Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the enzyme encoded by Dgat1 acts as a retinol acyltransferase in murine epidermis, protecting against retinoid toxicity and alopecia by preventing retinol accumulation.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

This study identified novel compound heterozygous mutations in the hairless gene among a non-consanguineous Chinese family with congenital atrichia, illustrating phenotypic variations due to founder or modifier genes.

A child on life support experienced rapid hair loss due to severe illness affecting hair growth.

In this study, oleanolic acid was found to enhance hair follicle growth and promote hair matrix cell proliferation via the Wnt/β-catenin pathway in a human hair follicle organ culture model.

In this study, researchers showed that the CAP1 gene regulates root hair growth in plants by modulating cytoplasmic ammonium levels and maintaining calcium gradients, highlighting its role in ammonium homeostasis.

This study found that CD44 and CD49d together enhance signaling pathways in lymphocytes in mice with alopecia areata, influencing their activation and function.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This article discusses the development of the Alopecia Areata Children's Quality of Life Index and highlights its potential importance for assessing the psychosocial burden in pediatric cases, without providing clinical results.

This study found that in male androgenic alopecia, the androgen receptor coactivator ARA70/ELE1 exhibits differential expression patterns, suggesting its involvement in the condition.

This abstract provides no clinical results; it describes terms and navigation options for the JAMA network and its publications.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that introducing rat ornithine transcarbamylase gene into spf-ash mice improved liver and intestinal enzyme activity and normalized some metabolic indicators.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study found that loss of the ACER1 gene in mice led to increased ceramide levels and progressive hair loss, highlighting ACER1's role in maintaining hair follicle stem cell homeostasis.

This case report found that a child with acrodermatitis enteropathica showed significant improvement in symptoms after continuous zinc supplementation and identified two SLC39A4 mutations through genetic sequencing.

Blocking adenosine A2B receptor may prevent or treat hearing loss.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

This study found that a specific fragment of AIMP1 secreted by hair follicle stem cells can stimulate dermal papilla cells and promote hair regrowth.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

This study found that overexpression of ornithine decarboxylase and activated Ha-ras together led to a high rate of tumor development in a mouse model without additional carcinogens.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

This case report highlights a rare presentation of APS-1 in a 28-year-old Pakistani male with cardiovascular and pulmonary symptoms, illustrating the importance of early recognition and multidisciplinary management for improved patient outcomes.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.